170 related articles for article (PubMed ID: 38066476)
1. A differential diagnosis between uterine leiomyoma and leiomyosarcoma using transcriptome analysis.
Kim K; Kim S; Ahn T; Kim H; Shin SJ; Choi CH; Park S; Kim YB; No JH; Suh DH
BMC Cancer; 2023 Dec; 23(1):1215. PubMed ID: 38066476
[TBL] [Abstract][Full Text] [Related]
2. Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling.
Quade BJ; Wang TY; Sornberger K; Dal Cin P; Mutter GL; Morton CC
Genes Chromosomes Cancer; 2004 Jun; 40(2):97-108. PubMed ID: 15101043
[TBL] [Abstract][Full Text] [Related]
3. Identification of a novel diagnostic gene expression signature to discriminate uterine leiomyoma from leiomyosarcoma.
Adams CL; Dimitrova I; Post MD; Gibson L; Spillman MA; Behbakht K; Bradford AP
Exp Mol Pathol; 2019 Oct; 110():104284. PubMed ID: 31301306
[TBL] [Abstract][Full Text] [Related]
4. Molecular and immunohistochemical evidence for the origin of uterine leiomyosarcomas from associated leiomyoma and symplastic leiomyoma-like areas.
Mittal KR; Chen F; Wei JJ; Rijhvani K; Kurvathi R; Streck D; Dermody J; Toruner GA
Mod Pathol; 2009 Oct; 22(10):1303-11. PubMed ID: 19633649
[TBL] [Abstract][Full Text] [Related]
5. Identification of uterine leiomyoma-specific marker genes based on DNA methylation and their clinical application.
Sato S; Maekawa R; Yamagata Y; Tamura I; Lee L; Okada M; Jozaki K; Asada H; Tamura H; Sugino N
Sci Rep; 2016 Aug; 6():30652. PubMed ID: 27498619
[TBL] [Abstract][Full Text] [Related]
6. Integrative Genomic and Transcriptomic Profiling Reveals a Differential Molecular Signature in Uterine Leiomyoma versus Leiomyosarcoma.
Machado-Lopez A; Alonso R; Lago V; Jimenez-Almazan J; Garcia M; Monleon J; Lopez S; Barcelo F; Torroba A; Ortiz S; Domingo S; Simon C; Mas A
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216305
[TBL] [Abstract][Full Text] [Related]
7. The differential diagnoses of uterine leiomyomas and leiomyosarcomas using DNA and RNA sequencing.
Mas A; Alonso R; Garrido-Gómez T; Escorcia P; Montero B; Jiménez-Almazán J; Martín J; Pellicer N; Monleón J; Simón C
Am J Obstet Gynecol; 2019 Oct; 221(4):320.e1-320.e23. PubMed ID: 31121144
[TBL] [Abstract][Full Text] [Related]
8. [Benign metastatic leiomyoma of the corpus uteri].
Andreeva IuIu; Danilova NV; Shikeeva AA; Kekeeva TV; Zavalishina LE; Frank GA
Arkh Patol; 2012; 74(6):39-43. PubMed ID: 23383444
[TBL] [Abstract][Full Text] [Related]
9. Potential role of preoperative serum CA125 for the differential diagnosis between uterine leiomyoma and uterine leiomyosarcoma.
Juang CM; Yen MS; Horng HC; Twu NF; Yu HC; Hsu WL
Eur J Gynaecol Oncol; 2006; 27(4):370-4. PubMed ID: 17009628
[TBL] [Abstract][Full Text] [Related]
10. Molecular Insights in Uterine Leiomyosarcoma: A Systematic Review.
Sparić R; Andjić M; Babović I; Nejković L; Mitrović M; Štulić J; Pupovac M; Tinelli A
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077127
[TBL] [Abstract][Full Text] [Related]
11. Transient shrinkage of a uterine leiomyosarcoma treated with GnRH agonist for a presumed uterine leiomyoma: comparison of magnetic resonance imaging finding before and during GnRH agonist treatment.
Kawamura N; Iwanaga N; Hada S; Maeda K; Sumi T; Ishiko O; Ogita S
Oncol Rep; 2001; 8(6):1255-7. PubMed ID: 11605044
[TBL] [Abstract][Full Text] [Related]
12. Uterine leiomyosarcoma diagnosed during treatment with agonist of luteinizing hormone-releasing hormone for presumed uterine fibroid.
Loong EP; Wong FW
Fertil Steril; 1990 Sep; 54(3):530-1. PubMed ID: 2118862
[TBL] [Abstract][Full Text] [Related]
13. Molecular prognostication of uterine smooth muscle neoplasms: From CGH array to CINSARC signature and beyond.
Croce S; Chibon F
Genes Chromosomes Cancer; 2021 Mar; 60(3):129-137. PubMed ID: 33099852
[TBL] [Abstract][Full Text] [Related]
14. Chromosome aberrations in uterine smooth muscle tumors: potential diagnostic relevance of cytogenetic instability.
Fletcher JA; Morton CC; Pavelka K; Lage JM
Cancer Res; 1990 Jul; 50(13):4092-7. PubMed ID: 2354458
[TBL] [Abstract][Full Text] [Related]
15. Integrated histologic and molecular analysis of uterine leiomyosarcoma and 2 benign variants with nuclear atypia.
Gao T; Finkelman BS; Ban Y; Li Y; Yin P; Bulun SE; Lu X; Ha C; Wei JJ
Cancer Sci; 2021 May; 112(5):2046-2059. PubMed ID: 33338329
[TBL] [Abstract][Full Text] [Related]
16. MED12 mutations in leiomyosarcoma and extrauterine leiomyoma.
Ravegnini G; Mariño-Enriquez A; Slater J; Eilers G; Wang Y; Zhu M; Nucci MR; George S; Angelini S; Raut CP; Fletcher JA
Mod Pathol; 2013 May; 26(5):743-9. PubMed ID: 23222489
[TBL] [Abstract][Full Text] [Related]
17. Differentiation of Uterine Leiomyosarcoma from Atypical Leiomyoma: Diagnostic Accuracy of Qualitative MR Imaging Features and Feasibility of Texture Analysis.
Lakhman Y; Veeraraghavan H; Chaim J; Feier D; Goldman DA; Moskowitz CS; Nougaret S; Sosa RE; Vargas HA; Soslow RA; Abu-Rustum NR; Hricak H; Sala E
Eur Radiol; 2017 Jul; 27(7):2903-2915. PubMed ID: 27921159
[TBL] [Abstract][Full Text] [Related]
18. A uterine leiomyoma in which a leiomyosarcoma with osteoclast-like giant cells and a metastasis of a ductal breast carcinoma are present.
van Meurs HS; Dieles JJ; Stel HV
Ann Diagn Pathol; 2012 Jan; 16(1):67-70. PubMed ID: 21216642
[TBL] [Abstract][Full Text] [Related]
19. Molecular differential diagnosis of uterine leiomyomas and leiomyosarcomas.
Mas A; Simón C
Biol Reprod; 2019 Dec; 101(6):1115-1123. PubMed ID: 30184111
[TBL] [Abstract][Full Text] [Related]
20. Inefficiency of ulipristal acetate on uterus leiomyomas as an additional sign to suspect leiomyosarcoma.
Kadhel P; Smail M; Borja De Mozota D
J Gynecol Obstet Hum Reprod; 2017 Sep; 46(7):609-611. PubMed ID: 28647614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
